- 193 views
- 408 downloads
pH-responsive microencapsulation systems for oral delivery of biopharmaceuticals
-
- Author / Creator
- Homayun, Bahman
-
Oral delivery is the most attractive drug administration route due to many specific advantages. Ease of administration, large and diverse absorption surface area, applicability for solid formulations, patients’ compliance, and intensified immune response due to mucosal effects are usually regarded as the main advantages of this route. On the other hand, gastric instability, mucus layer and tight junctions of the small intestine are principal biological barriers against this route. Additionally, technical challenges such as drug denaturation through the microencapsulation process, insufficient loading capacity, unsatisfactory preservation efficiency, and limited fabrication throughput of the systems are considerable challenges against the commercialization of oral delivery systems. Previously in this group, pored microencapsulation was developed to specifically address two principle issues with available oral delivery systems: 1) drug denaturation through the microencapsulation process due to contact with organic solvents, and 2) drug instability in harsh gastric environment. In fact, pored microencapsulation system completely excluded the drug molecules from the fabrication process of the microparticles (MPs). As a consequence, the drugs could be loaded into the MPs through their surface pores in favorable environmental conditions, eliminating any concerns about technical drug denaturation. The surface pores of the MPs were subsequently closed through freeze drying to properly isolate the loaded drugs from the surrounding environment. Accordingly, the drugs were properly protected in stomach, and once the MPs reached the absorption target in small intestine, the surface pores would open due to their pH-responsive nature and release the drug. Although pored microencapsulation systems have successfully resolved the concerns associated with drug denaturation during the fabrication process and preserved the drug to acceptable levels, they still suffer from the other problems mentioned before, including insufficient loading capacity and low throughput. Additionally, this system could not properly deal with biological barriers such as mucus, which can dramatically reduce the absorption efficiency of the drug at the target. With all these in mind, this project was focused on the development novel architectures of oral pored microparticles, which can address the remaining problems as well.
In the first step, a new swelling/solvent evaporation protocol was developed as a facile fabrication process of MPs with pH-responsive surface pores. The MPs fabricated through this process showed up to 65% preservation efficiency of the loaded ingredients against simulated gastric environment and capability for the encapsulation of ingredients with a range of various sizes (100 nm to 4 µm). Although this part of the project led to improvements in both the fabrication throughput of the system as well as its preservation efficiency, the new MPs were still suffering from insufficient loading efficiency and lack of features for dealing with biological barriers at the absorption site.
In the next step of the project, emulsion solvent evaporation protocol for the fabrication of the MPs, and new features were included in the system for co-delivery applications. As a consequence, mucolytic enzymes could be simultaneously delivered to dilute the mucus layer at the absorption site of the drug, make the epithelial layer beneath the mucus easily accessible and consequently improve the absorption efficiency of the drug at the target. The average diameter of the MPs prepared through this process was successfully increased up to 15x to increase the loading capacity of the system. Indeed, since the main drug in this system is loaded into the interior void space of the MPs, increasing the average diameter of the MPs would be the most effective key to address the issues with loading capacity. As a results, the loading efficiency of the system was improved up to 50x for different sizes of the drug molecules. Additionally, the new fabrication protocol showed promising potentials for scaling up and commercialization. Also, ex-vivo analyses confirmed that the new feature of the system can effectively remove the mucus barrier against the absorption of the drugs. The drug molecules released form the MPs also showed 60% remaining activity, confirming the potentials of the system for further investigations as a new and effective oral delivery architecture.
In the final step, the MPs needed to be coated for further protection in mouth cavity, saliva and esophagus. In summary, the present work presents a new comprehensive oral administration system for preserving vulnerable drug molecules against microencapsulation process and harsh biological media and safely delivering them to the absorption site in the small intestine. -
- Subjects / Keywords
-
- Graduation date
- Fall 2019
-
- Type of Item
- Thesis
-
- Degree
- Doctor of Philosophy
-
- License
- Permission is hereby granted to the University of Alberta Libraries to reproduce single copies of this thesis and to lend or sell such copies for private, scholarly or scientific research purposes only. Where the thesis is converted to, or otherwise made available in digital form, the University of Alberta will advise potential users of the thesis of these terms. The author reserves all other publication and other rights in association with the copyright in the thesis and, except as herein before provided, neither the thesis nor any substantial portion thereof may be printed or otherwise reproduced in any material form whatsoever without the author's prior written permission.